Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
3.720
-0.050 (-1.33%)
At close: Nov 20, 2026, 4:00 PM EST
3.710
-0.010 (-0.27%)
After-hours: Nov 20, 2026, 7:56 PM EST
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
According to 13 analysts polled by S&P Global, Taysha Gene Therapies stock has a consensus rating of "Strong Buy" and an average price target of $13. The average 1-year stock price forecast is 249.46% higher than the current stock price, while the lowest is $9.00 (+141.94%) and the highest is $19 (+410.75%).
Price Target: $13 (+249.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 9 | 9 | 10 | 10 | 10 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 12 | 12 | 13 | 13 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +222.58% | Nov 20, 2026 |
| BMO Capital | BMO Capital | Buy Maintains $14 | Buy | Maintains | $14 | +276.34% | Nov 13, 2026 |
Unknown Analyst Wells Fargo No rating | Wells Fargo | Buy Reiterates $11 | Buy | Reiterates | $11 | +195.70% | Nov 13, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Reiterates $17 | Buy | Reiterates | $17 | +356.99% | Nov 13, 2026 |
| Wolfe Research | Wolfe Research | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Sep 17, 2026 |
Financial Forecast
Revenue This Year
300.00K
from 9.77M
Decreased by -96.93%
Revenue Next Year
19.47M
from 300.00K
Increased by 6,389.64%
EPS This Year
-0.43
from -0.32
EPS Next Year
-0.39
from -0.43
EPS and Forward PE are based on non-GAAP adjusted numbers.